Shipra Gandhi, MD, MS

February 27, 2026

Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.

October 3, 2025

The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.